Get the Stockscreener App
1.91
5.91%
-0.12
After Hours:
1.92
0.01
+0.52%
Mustang Bio Inc stock is traded at $1.91, with a volume of 274.82K.
It is down -5.91% in the last 24 hours and up +85.44% over the past month.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
See More
Previous Close:
$2.03
Open:
$2.02
24h Volume:
274.82K
Relative Volume:
0.05
Market Cap:
$6.75M
Revenue:
-
Net Income/Loss:
$-23.42M
P/E Ratio:
-0.0245
EPS:
-78
Net Cash Flow:
$-16.67M
1W Performance:
-12.39%
1M Performance:
+85.44%
6M Performance:
-60.13%
1Y Performance:
-89.07%
1-Day Range:
$1.90
$2.0885
1-Week Range:
$1.90
$2.1899
52-Week Range:
$0.8926
$21.95
Mustang Bio Inc Stock (MBIO) Company Profile
Name
Mustang Bio Inc
Sector
Industry
Phone
(781) 652-4500
Address
377 PLANTATION STREET, WORCESTER, NY
Compare MBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
1.91 | 8.89M | 0 | -23.42M | -16.67M | -78.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Oct-02-20 | Initiated | B. Riley FBR | Buy |
| Nov-20-19 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-19 | Initiated | H.C. Wainwright | Buy |
| Jun-21-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Initiated | Oppenheimer | Outperform |
View All
Mustang Bio Inc Stock (MBIO) Latest News
What analysts say about Mustang Bio Inc. stockOverwhelming financial success - Autocar Professional
Mustang Bio Inc. Stock Analysis and ForecastOutstanding stock performance - Autocar Professional
What drives Mustang Bio Inc. stock priceExceptional gains - jammulinksnews.com
Is Mustang Bio Inc. a good long term investmentExceptional risk-adjusted gains - jammulinksnews.com
Mustang Bio (NASDAQ:MBIO) Upgraded to “Hold” at Wall Street Zen - Defense World
How Mustang Bio Inc. stock performs during market volatility200 Percent Gain Alert - Newser
Why Mustang Bio Inc. stock attracts strong analyst attentionSafe Entry High Exit Alerts - Newser
What makes Mustang Bio Inc. stock price move sharplyTriple Digit Return Forecasts - Newser
MBIO Stock: Exploring Mustang Bio Inc’s Growth - investchronicle.com
Mustang Bio Shares Skyrocket After Orphan Drug Designation - StocksToTrade
Mustang Bio’s Shares Skyrocket as FDA Grants Orphan Drug Designation - timothysykes.com
Promising Small Cap Stocks Worth Watching – July 7th - Defense World
Top Penny Stocks To Follow Now – July 7th - Defense World
Mustang Bio’s Meteoric Surge: What’s Driving Up MBIO? - StocksToTrade
Mustang Bio’s Stock Soars: What’s Driving the Surge? - timothysykes.com
Mustang Bio Receives FDA Orphan Drug Designation - TipRanks
Best Medical Stocks To Follow Today – July 7th - Defense World
Promising Pharmaceutical Stocks To Consider – July 7th - Defense World
Top Biotech Stocks To Research – July 7th - Defense World
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On - Benzinga
Mustang Bio Ignites Bullish Retail Buzz As FDA Grants Orphan Status To Brain Cancer Drug - NewsBreak: Local News & Alerts
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - TradingView
Mustang Bio Stock Jumps 180% After FDA Grants Orphan Drug Status to Brain Cancer Drug - inkl
Why Did Mustang Bio Plunge 11.68% After 196.21% Surge? - AInvest
Biotech Stock Analysis: MBIO Soars after FDA Grants Orphan Drug Designation - Markets.com
Market Wrap | US Stocks Slide as Fed Rate Cut Hints Emerge Palantir and Mustang Bio Soar - AInvest
Mustang Bio (MBIO) Stock Explodes 260% After FDA Grants Key Cancer Drug Designation - Benzinga
Dow Dips 1%; Mustang Bio Shares Spike Higher - inkl
Mustang Bio Inc Stock (MBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):